tiprankstipranks
Trending News
More News >
I-Mab Adr (IMAB)
:IMAB
US Market
Advertisement

I-MAB (IMAB) AI Stock Analysis

Compare
343 Followers

Top Page

IMAB

I-MAB

(NASDAQ:IMAB)

Rating:45Neutral
Price Target:
The overall stock score of 45 reflects I-MAB's substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
Positive Factors
Clinical Efficacy
Givastomig demonstrates an 83% overall response rate, which is notably higher compared to a competitor's treatment response rate of approximately 40%.
Patient Coverage
Givastomig's ability to generate responses across a wider CLDN18.2 expression spectrum could potentially more than double the addressable patient population for targeted therapy.
Safety Profile
Givastomig continues to show a differentiated and manageable safety profile with no dose-limiting toxicities, supporting its suitability for broader clinical use.
Negative Factors
Competitor Comparison
For Givastomig, it is crucial to demonstrate a median progression-free survival comparable to that seen with zolbetuximab plus chemotherapy.
Market Competition
Givastomig's market potential may face challenges if it cannot clearly differentiate its efficacy and safety profile from existing CLDN18.2-targeted therapies like zolbetuximab.

I-MAB (IMAB) vs. SPDR S&P 500 ETF (SPY)

I-MAB Business Overview & Revenue Model

Company DescriptionI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyI-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royalties from these partnerships as its drug candidates progress through clinical trials and reach the market. Additionally, I-MAB might gain revenue from licensing its proprietary technologies and intellectual property to other entities. Significant partnerships with global pharmaceutical companies facilitate the advancement of its pipeline, contributing to its earnings potential.

I-MAB Financial Statement Overview

Summary
I-MAB faces substantial financial challenges, particularly in terms of profitability and cash flow generation. Although the company benefits from a strong liquidity position and low leverage, its ability to generate positive earnings and cash flows remains a concern. The volatility in revenue and consistent losses highlight the need for strategic adjustments to improve financial performance.
Income Statement
20
Very Negative
The company's income statement indicates significant challenges, with substantial negative net income and EBIT margins over recent years. Although there was a positive revenue figure in 2023, the revenue growth has been erratic, with a substantial decline from 2020 to 2022 followed by a modest recovery. Gross profit margins have been inconsistent, which, coupled with negative net profit and EBIT margins, underscores profitability issues.
Balance Sheet
50
Neutral
The balance sheet shows a strong equity base relative to liabilities, with a debt-to-equity ratio remaining low due to minimal debt levels. However, the equity ratio has been declining, indicating diminishing equity relative to total assets. The company maintains a significant cash position, which is a positive sign of liquidity.
Cash Flow
30
Negative
Cash flow analysis reveals persistent negative free cash flows, indicating challenges in generating sufficient cash from operations. The absence of operating cash flow data for 2023 makes it difficult to assess the recent cash generation ability. Historical trends show negative operating cash flow, impacting the overall cash flow position negatively.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.0027.64M-221.56M88.03M1.54B
Gross Profit0.0027.64M-248.80M41.59M1.54B
EBITDA-373.45M-1.21B-1.94B-2.06B168.31M
Net Income-162.26M-1.47B-2.51B-2.33B470.92M
Balance Sheet
Total Assets212.68M2.61B4.07B5.63B6.33B
Cash, Cash Equivalents and Short-Term Investments173.40M2.29B3.45B4.28B4.79B
Total Debt3.88M18.89M74.99M112.45M13.60M
Total Liabilities11.52M894.81M1.07B1.04B706.65M
Stockholders Equity201.16M1.72B3.01B4.59B5.63B
Cash Flow
Free Cash Flow-52.72M-72.86M-1.15B-1.00B425.55M
Operating Cash Flow-52.67M-72.70M-1.10B-973.09M433.56M
Investing Cash Flow-136.01M102.52M458.38M-727.21M-201.90M
Financing Cash Flow-335.00K7.57M42.36M593.92M3.44B

I-MAB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.11
Price Trends
50DMA
1.91
Positive
100DMA
1.37
Positive
200DMA
1.22
Positive
Market Momentum
MACD
0.02
Positive
RSI
49.49
Neutral
STOCH
26.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMAB, the sentiment is Neutral. The current price of 2.11 is below the 20-day moving average (MA) of 2.22, above the 50-day MA of 1.91, and above the 200-day MA of 1.22, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.49 is Neutral, neither overbought nor oversold. The STOCH value of 26.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMAB.

I-MAB Risk Analysis

I-MAB disclosed 91 risk factors in its most recent earnings report. I-MAB reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We face significant risks related to the transition of our business focus to the U.S. market and our business and prospects may be materially and adversely affected. Q4, 2023
2.
We face risks associated with the divestiture of the Greater China assets and business operations to I-Mab Hangzhou. Q4, 2023
3.
Evolvement in the U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. Q4, 2023

I-MAB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥351.06B11.13-2.99%2.50%11.77%-10.16%
45
Neutral
$166.57M-22.38%
44
Neutral
$90.77M-55.14%-99.43%-69.40%
43
Neutral
$103.95M-62.34%86.65%
37
Underperform
$135.64M-154.55%19.70%
37
Underperform
$74.45M-55.59%65.02%
33
Underperform
$261.17M-125.43%2.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMAB
I-MAB
2.11
0.72
51.80%
ACHV
Achieve Life Sciences
2.73
-2.16
-44.17%
VOR
Vor Biopharma
2.09
1.14
120.00%
ADAG
Adagene
1.93
-0.60
-23.72%
CNTX
Context Therapeutics
0.83
-1.61
-65.98%
ZURA
Zura Bio
1.69
-2.08
-55.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 31, 2025